Literature DB >> 32113937

Global, regional and national burden of pancreatic cancer, 1990 to 2017: Results from the Global Burden of Disease Study 2017.

Xiang Chen1, Bin Yi2, Zhongtao Liu1, Heng Zou1, Jiangjiao Zhou1, Zijian Zhang1, Li Xiong1, Yu Wen3.   

Abstract

BACKGROUND: The global burden of pancreatic cancer (PCa) continues to grow. Detailed data on PCa epidemiology are essential for policy-making and appropriate healthcare resource allocation.
METHODS: Estimates of incidence, death and disability-adjusted life years (DALYs) of PCa from 1990 to 2017 were collected from the Global Burden of Disease Study 2017. Decomposition analysis was conducted to detect the contributing factors related to PCa incidence variation. The estimated annual percentage change (EAPC) was calculated to quantify the PCa epidemiology trends over a specified interval.
RESULTS: Globally, the incidence of PCa cases increased by 129.1% to 447 664 664 (95% uncertainty interval (UI) 438 597-456 295), death increased by 125.2% to 441 082 082 (95% UI 448 960-432 833), and DALYs increased by 107.3% to 9 080 004 (95% UI 8 894 128-9 256 346) between 1990 and 2017. Relatively higher sociodemographic index (SDI) regions were observed with greater incidences, more deaths and a greater number of DALYs of PCa, but relatively lower SDI regions experienced a sharply increasing trend in these measures. Decomposition analysis indicated that the global increase in PCa incidence was driven by the aging population from 2007 to 2017, especially in higher SDI regions. In addition, a significant negative correlation was found between EAPC and ASIR (in 1990) (r = -0.56, P < 0.001).
CONCLUSIONS: PCa remains a major public health burden globally. The unfavorable trend in PCa suggesting that further study for prevention should be conducted to forestall the increase in pancreatic cancer.
Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Global burden of disease; Incidence; Mortality; Pancreatic cancer; Prevention

Mesh:

Year:  2020        PMID: 32113937     DOI: 10.1016/j.pan.2020.02.011

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  7 in total

Review 1.  Emerging Role of Exosomal-Derived Long Noncoding RNAs in Human PDAC.

Authors:  Di Long; Xiao Dong Tian; Yin-Mo Yang
Journal:  Visc Med       Date:  2021-12-20

Review 2.  Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?

Authors:  Chenqi Wang; Guang Tan; Jie Zhang; Bin Fan; Yunlong Chen; Dan Chen; Lili Yang; Xiang Chen; Qingzhu Duan; Feiliyan Maimaiti; Jian Du; Zhikun Lin; Jiangning Gu; Haifeng Luo
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

3.  High RAS-related protein Rab-7a (RAB7A) expression is a poor prognostic factor in pancreatic adenocarcinoma.

Authors:  Qi Liu; Yang Bai; Xiaoyi Shi; Danfeng Guo; Yong Wang; Yun Wang; Wen-Zhi Guo; Shuijun Zhang
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

4.  The spatiotemporal dynamics of lung cancer: 30-year trends of epidemiology across 204 countries and territories.

Authors:  Xiang Chen; Shaoyan Mo; Bin Yi
Journal:  BMC Public Health       Date:  2022-05-16       Impact factor: 4.135

5.  Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis.

Authors:  Yaolin Xu; Yueming Zhang; Siyang Han; Dayong Jin; Xuefeng Xu; Tiantao Kuang; Wenchuan Wu; Dansong Wang; Wenhui Lou
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

6.  Circular RNA hsa_circ_0007367 promotes the progression of pancreatic ductal adenocarcinoma by sponging miR-6820-3p and upregulating YAP1 expression.

Authors:  Haocheng Zhang; Xiaolei Ma; Luning Wang; Xinyu Li; Di Feng; Meiming Liu; Jiayang Li; Mengxing Cheng; Na Song; Xinxia Yang; Lina Ba; Yating Lei; Ruipu Zhang; Yunxiao Zhu; Wenxiao Xu; Guofen Qiao
Journal:  Cell Death Dis       Date:  2022-08-25       Impact factor: 9.685

7.  Associations between genetic variants of KIF5B, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk.

Authors:  Lingling Zhao; Hongliang Liu; Sheng Luo; Patricia G Moorman; Kyle M Walsh; Wei Li; Qingyi Wei
Journal:  Cancer Med       Date:  2020-11-16       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.